Nkarta Therapeutics

Edit info

Founded: 2015

Location: South SF, CA

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: AML , MDS

Drug types: ONC

Lead product: NKX101

Funding: $200M stock Apr 2022; $289.8M IPO Jul 2020; $114M B Sep 2019; $11M 2015

Investors: Samsara, NEA Ventures, SR One, Novo Holdings, Amgen Ventures, Deerfield Management, Life Science Partners, Logos Capital and RA Capital Management

nkartatx.com

linkedin.com

job board

Business:

Allogeneic cellular immunotherapy platform

Drug notes:

Also Clin0 multiple cancers; NKX019 Clin1 B cell malignancies; undisclosed RD oncology; undisclosed RD undisclosed

About:

Nkarta Therapeutics is advancing the development of natural killer (NK) cell therapies. NK cells are the immune system’s first responders against diseases and pathogens, with an inherent ability to target tumor cells. Nkarta is using their proprietary technology to harness the power of NK cells and enhance their ability to search and destroy tumor cells. This involves redesigning NK cells to maximize their therapeutic effect through robust expansion, enhanced targeting and extended persistence to create a sustained anti-cancer immune-mediated attack. Nkarta’s goal is to offer a versatile and robust approach to cancer therapy to improve patient outcomes.